Free Trial Information
BioCentury | Jul 12, 2010
Strategy

Biogen Idec's Agenda

...for moderate and severe psoriasis and Phase II testing for RRMS 2006 Conforma Therapeutics Corp. $150M [acquisition] Conforma...
Read More
BioCentury | Jan 11, 2010
Strategy

Evolution of Biogen Idec's Pipeline

...with Facet Biotech Corp. (NASDAQ:FACT) HSP 90 inhibitor Solid tumors Ph II 2006 acquisition of Conforma Therapeutics Corp....
Read More
BioCentury | May 26, 2008
Finance

Ebb & Flow

...Management as a life sciences venture partner. He was president and CEO of cancer company Conforma...
Read More
BioCentury | Apr 14, 2008
Finance

Ebb & Flow

...portfolio companies: Cabrellis , which was acquired by Pharmion for $59 million in cash; and Conforma...
Read More
BioCentury | Sep 24, 2007
Finance

Domain exits

...Domain exits Company Description Cabrellis [acq'd by Pharmion] Spun out of Conforma when that company was...
...infections Cerexa [acq'd by Forest ] Had ceftaroline, a cephalosporin antibiotic in Phase III testing Conforma...
Read More
BioCentury | Sep 3, 2007
Strategy

Back to School 2007: Innovation & leadership

Over the past two years, Back to School has been exploring the relationship between innovation and the economic returns from drug development and the creation of patient value. These discussions have argued that as pricing...
Read More
BioCentury | Jun 4, 2007
Finance

Ebb & Flow

...Fumapharm for an undisclosed amount of stock. And in May 2006, BIIB acquired cancer company Conforma...
Read More
BioCentury | Feb 26, 2007
Tools & Techniques

Hsp90 on the brain

...PIN1 resulted in decreased p-tau levels. The researchers worked with EC102, an Hsp90 inhibitor from Conforma Therapeutics Corp....
...Cambridge, Mass.). Although BIIB is not currently advancing EC102, the researchers were already familiar with Conforma’s...
Read More
BioCentury | Jan 8, 2007
Finance

Ebb & Flow

...company Optimer , which filed in November to go public. In May, ProQuest also exited Conforma...
Read More
BioCentury | Dec 4, 2006
Strategy

Reviving the model

...Cabrellis for $59 million in cash (see BioCentury, Nov. 20) . Cabrellis spun out of Conforma...
Read More
Items per page:
1 - 10 of 53
BioCentury | Jul 12, 2010
Strategy

Biogen Idec's Agenda

...for moderate and severe psoriasis and Phase II testing for RRMS 2006 Conforma Therapeutics Corp. $150M [acquisition] Conforma...
Read More
BioCentury | Jan 11, 2010
Strategy

Evolution of Biogen Idec's Pipeline

...with Facet Biotech Corp. (NASDAQ:FACT) HSP 90 inhibitor Solid tumors Ph II 2006 acquisition of Conforma Therapeutics Corp....
Read More
BioCentury | May 26, 2008
Finance

Ebb & Flow

...Management as a life sciences venture partner. He was president and CEO of cancer company Conforma...
Read More
BioCentury | Apr 14, 2008
Finance

Ebb & Flow

...portfolio companies: Cabrellis , which was acquired by Pharmion for $59 million in cash; and Conforma...
Read More
BioCentury | Sep 24, 2007
Finance

Domain exits

...Domain exits Company Description Cabrellis [acq'd by Pharmion] Spun out of Conforma when that company was...
...infections Cerexa [acq'd by Forest ] Had ceftaroline, a cephalosporin antibiotic in Phase III testing Conforma...
Read More
BioCentury | Sep 3, 2007
Strategy

Back to School 2007: Innovation & leadership

Over the past two years, Back to School has been exploring the relationship between innovation and the economic returns from drug development and the creation of patient value. These discussions have argued that as pricing...
Read More
BioCentury | Jun 4, 2007
Finance

Ebb & Flow

...Fumapharm for an undisclosed amount of stock. And in May 2006, BIIB acquired cancer company Conforma...
Read More
BioCentury | Feb 26, 2007
Tools & Techniques

Hsp90 on the brain

...PIN1 resulted in decreased p-tau levels. The researchers worked with EC102, an Hsp90 inhibitor from Conforma Therapeutics Corp....
...Cambridge, Mass.). Although BIIB is not currently advancing EC102, the researchers were already familiar with Conforma’s...
Read More
BioCentury | Jan 8, 2007
Finance

Ebb & Flow

...company Optimer , which filed in November to go public. In May, ProQuest also exited Conforma...
Read More
BioCentury | Dec 4, 2006
Strategy

Reviving the model

...Cabrellis for $59 million in cash (see BioCentury, Nov. 20) . Cabrellis spun out of Conforma...
Read More
Items per page:
1 - 10 of 53